Search Results

CXCR4 takes on a nuclear role in red blood cell maturation CXCL13/CXCR5 emerges as a high-potential pain target ST171, a biased 5‑HT1A agonist, delivers selective pain relief in preclinical models Dr.GPCR Blocking this chemokine axis reduces pain  hypersensitivity by dampening neuroinflammation and glial This novel agonist activates Gi/o selectively , avoiding β-arrestin and showing strong pain relief in

After years of living with unresolved pain following surgery for a pilonidal cyst, Alex was left without This is a story about how chronic pain doesn't just shape lives — it reshapes careers. “I wasn’t able to get stronger pain meds,” he said. “So I had to understand the biology myself.” Mike Caterina on pain mechanisms in the peripheral nervous system. , pain neuroscience

Join the #GPCR movement by becoming a site member for FREE!

Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr

Boston, MA and San Diego, CA — [February 18, 2026] — Dr. GPCR , the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. This partnership is designed to support the GPCR research community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident decision-making across the discovery and development continuum. Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most comprehensive GPCR assay portfolios, encompassing over 90% of the human GPCRome with assays for human receptors, species orthologs, and orphan receptors across various cellular backgrounds. Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical and biotechnology companies worldwide. Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification and validation to high-throughput screening (HTS), lead optimization, safety assessment, and regulatory-compliant potency testing. These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed publications and billions of screened data points. “Eurofins DiscoverX is distinguished by its deep GPCR expertise and close collaboration with customers,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR . “They offer more than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR research with confidence.” “Dr. GPCR plays a critical role in educating and connecting the global GPCR community,” said Geoffrey Donsimoni, GPCR Marketing Director at Eurofins DiscoverX . “Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world applications that help researchers fully leverage GPCR assay technologies across discovery and development.” Together, Dr. GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design and data interpretation. To explore Eurofins DiscoverX GPCR assay solutions and curated resources, visit: https://www.ecosystem.drgpcr.com/eurofins-discoverx To learn more about Dr. GPCR’s educational programs and global GPCR community, visit https://www.ecosystem.drgpcr.com About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem, Dr. GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery. About Eurofins DiscoverX Eurofins DiscoverX is a global leader in GPCR cell-based assay technologies, providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development. With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.

🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr

Watch Episode 170 Thinking Differently Pain research has long followed a familiar route: from molecule conventional bottom-up approach often fails to deliver therapies that truly help patients, especially in the pain patient-centric and behavior-first approach uncovered robust gene expression signatures  linked to pain Why This Approach Matters In pain research, bottom-up approaches often fail to translate. Alex Serafini makes the case for building pain research from the clinic down, not the bench up. _____

Watch Episode 170 What We’re Missing in Pain Research In GPCR drug discovery, receptors typically steal Signaling (RGS proteins)  might hold some of the most untapped therapeutic opportunities, particularly in pain Venetia Zachariou  introduced him to the power of RGS proteins — particularly RGS4  — in modulating pain models and hints that RGS proteins could modulate pain chronification itself . Serafini highlighted that in modern pain drug development, the field has remained too focused on ion

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. As a Dr. GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr. GPCR Newsletter , University Courses , and Podcast , as well as the searchable Dr. GPCR Ecosystem Directory —a centralized hub for tools, training, and technology. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,”  said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,”  said Wilson Gomes , CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,”  added Dr. Maria Majellaro , CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit  www.celtarys.com . For access to Dr. GPCR’s global network, educational content, and discovery tools, visit  ecosystem.drgpcr.com . ___________ About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 160 podcast episodes, live and on-demand educational programs, and a dynamic partner ecosystem, Dr. GPCR empowers scientists and companies advancing receptor biology and drug discovery. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development of optimal chemical tools for drug discovery. Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development, screening, and live-cell imaging.

of curiosity, persistence, and using science to meet unmet clinical needs, especially in the chronic pain For his postdoctoral training at Boston Children’s Hospital and Harvard Medical School, he joined the Clifford Woolf, a leader in pain biology. slow down or prevent good science from reaching patients — particularly in underfunded fields like pain seeds for what would later become Blue Therapeutics, a startup he co-founded to develop non-addictive pain

Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined

Company’s novel S1P1 receptor modulator being developed as a potential treatment for diabetic neuropathic pain

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer,

November 22, 2021 JUPITER, FL—Scientists at Scripps Research in Florida have created a collection of new pain-relieving

.- Jan Steyaert, scientific director of the VIB-VUB Center for Structural Biology, Vlaams Instituut Biotechnologie Jan Steyaert will be presented with the Gabbay Award at Brandeis University on October 27 when he will

a variety of potential clinical applications with a great interest in the treatment of neuropathic pain optimization, this series of compounds could represent potential clinically useful S1R ligands for pain

John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain These compounds may be a novel way to treat pain without the negative side effects of cannabinoids or

Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating

that contains various adhesion-related domains and a highly-conserved GPCR-autoproteolysis-inducing (GAIN The cleavage appears to occur at an atypical GPCR proteolysis site within the GAIN domain during an early

August 2022 "The calcium-permeable cation channel TRPM3 can be activated by heat and the endogenous steroid pregnenolone sulfate. TRPM3's best understood function is its role as a peripheral noxious heat sensor in mice. However, the channel is expressed in various tissues and cell types including neurons as well as glial and epithelial cells. TRPM3 expression patterns differ between species and change during development. Furthermore, a plethora of TRPM3 variants that result from alternative splicing have been identified and the majority of these isoforms are yet to be characterized. Moreover, the mechanisms underlying regulation of TRPM3 are largely unexplored. In addition, a micro-RNA gene (miR-204) is located within the TRPM3 gene. This complexity makes it difficult to obtain a clear picture of TRPM3 characteristics. However, a clear picture is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic target. Therefore, the newest data related to TRPM3 have to be discussed and to be put in context as soon as possible to be up-to-date and to accelerate the translation from bench to bedside. The aim of this review is to highlight recent results and developments with particular focus on findings from studies involving ocular tissues and cells or peripheral neurons of rodents and humans." Read more at the source #DrGPCR #GPCR #IndustryNews

Gain access to over 500 minutes of recorded classes in our  GPCR courses   taught by Drs. Join us for a stimulating conversation with Dr. Take Action Now and Join our Community of Learners! Protein-Coupled Receptors for New Therapeutic Options 📍  Boston, MA 📅 October 2 -3, 2024 Come and join to 22nd, 2024 Industry News Inversago Pharma’s INV-347 improves metabolic dysfunction in obese mice Aneesh

extensive research on The role of receptor activity-modifying proteins in obesity and diabetes mellitus Maleesha clinical development Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain

from new pipelines targeting obesity to significant collaborations in cardiometabolic disease, and gain Terry's Corner - Unlock the Power of Target Residence Time in Your GPCR Drug Discovery Pipeline Gain ➡️  Premium Members get 50%+ discount when they join Terry’s Corner. Why contribute: Join a global, like-minded GPCR community. GPCR University Course Attendee Ready to gain a competitive advantage?

Don't let misconceptions about receptor binding kinetics slow your progress—gain the clarity you need Premium Members get 50%+ discount when they join Terry’s Corner. Register and join your colleagues in September ➤ Why Dr. ” - DrGPCR University Course Attendee Get a competitive advantage—Join Dr. Gain the insights, tools, and connections you need to excel in your field and make your mark.

In this session, you’ll gain:   ✅ A framework for understanding when apparent multiple affinities really Join Now — Access Immediate, Actionable Insight   You’ll gain the insight needed to:   Interpret complex

Gain access to over 500 minutes of recorded classes in our  GPCR courses   taught by Drs. Join us for an exciting discussion with Dr. Terry Kenakin to gain insights and prepare for upcoming courses. Targeting G Protein-Coupled Receptors for New Therapeutic Options 📍  Boston, MA 📅 October 2 -3, 2024 Join parathyroid hormone receptor type 1 mutation: clinical features and functional analysis GPCRs in Neuroscience Gain

GPCR, is helping researchers worldwide gain access to customized, reliable assay tools without the delays

In this session, you’ll gain: ✅ A practical framework for understanding when a drug’s rate of binding You’ll gain clarity that accelerates your path from discovery to clinic: Know when your assays truly

Gain competitive clarity:  Learn how binding and function diverge, and why that divergence is the key whether your assay informs—or deceives. 💡 Premium Members also receive a 50%+ discount  when they join Each week, you gain curated intelligence across science, careers, and strategy: Deep-dive expert lectures Premium Membership ensures you never miss it. 🚀 Join PremiumToday ➤